Prevention of left ventricular remodelling after acute myocardial infarction: an update

Area of Science:

• Cardiology
• Pharmacology
• Regenerative Medicine

Background:

• Left ventricular remodeling begins after acute myocardial infarction, leading to heart failure.
• This process involves chamber dilation, increased wall stress, and impaired heart function.
• Neurohormonal activation and sympathetic stimulation contribute to post-infarction left ventricular dysfunction.

Purpose of the Study:

• To review recent patents and experimental studies on drugs preventing left ventricular remodeling.
• To explore novel therapeutic targets for reversing left ventricular remodeling.

Main Methods:

• Review of scientific literature, including patents and experimental studies.
• Analysis of pharmacological interventions targeting left ventricular remodeling.
• Evaluation of emerging regenerative and molecular targets.

Main Results:

• Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers are effective in modulating remodeling and reducing adverse events.
• High-risk patients were often excluded from trials, leaving clinical questions unanswered.
• Experimental data suggests stem cell transfer, oxidant stress pathways, inflammatory pathways, and matrix-metalloproteinase activation as new targets.

Conclusions:

• Established drug classes effectively manage left ventricular remodeling post-myocardial infarction.
• Further research is needed to address clinical uncertainties and explore novel therapeutic strategies.
• Emerging targets like stem cells and specific molecular pathways offer potential for reversing cardiac damage.